This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Summary: Hallin and colleagues demonstrate the preclinical activity of the KRASG12C-specific inhibitor MRTX849 in a series of in vitro and in vivo studies with supporting pilot clinical efficacy. Variable responsiveness despite effective KRASG12C inhibition highlights both the promise and potential need for combinatorial strategies to optimally target KRASG12C-driven cancers.
See related article by Hallin et al., p. 54.
Footnotes
Cancer Discov 2020;10:20–2
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
January 2020
Volume 10, Issue 1
Volume 10, Issue 1
Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond
Jump to section
Advertisement